1. This article examines the anti-SARS-CoV-2 cellular response after two and three doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
2. The results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4+Th1+T cell responses while the effect CD8 + T cell responses was marginal.
3. The authors declare potential competing interests, such as research funding from Institut Roche and travel grant from Gilead, non-financial support from MSD and research grants and non-financial support from Pfizer.
The article is generally reliable and trustworthy, as it is published in a reputable journal (Vaccine) and has been peer reviewed by experts in the field. The authors have declared any potential competing interests, which helps to ensure that their findings are unbiased. Furthermore, the article provides detailed information about the study design, methodology, results, and discussion of the implications of their findings.
However, there are some points of consideration that are missing or not explored fully enough in this article. For example, there is no mention of possible risks associated with taking multiple doses of the vaccine or how long it takes for immunity to be established after taking multiple doses. Additionally, there is no discussion of other factors that may influence the efficacy of the vaccine such as age or underlying health conditions. Finally, there is no exploration of counterarguments or alternative perspectives on this topic which could provide a more balanced view on this issue.